Koleen Eisele
YOU?
Author Swipe
View article: Supplemental figure 2 from Efficacy of SERD/SERM Hybrid-CDK4/6 Inhibitor Combinations in Models of Endocrine Therapy–Resistant Breast Cancer
Supplemental figure 2 from Efficacy of SERD/SERM Hybrid-CDK4/6 Inhibitor Combinations in Models of Endocrine Therapy–Resistant Breast Cancer Open
Supplemental figure 2: SERDs inhibit the constitutive activity of the clinically relevant Y537N,D538G ESR1 double mutant
View article: Supplemental figure 4 from Efficacy of SERD/SERM Hybrid-CDK4/6 Inhibitor Combinations in Models of Endocrine Therapy–Resistant Breast Cancer
Supplemental figure 4 from Efficacy of SERD/SERM Hybrid-CDK4/6 Inhibitor Combinations in Models of Endocrine Therapy–Resistant Breast Cancer Open
Supplemental figure 4: Evaluation of pharmacodynamics endpoints confirms on target activity of SERDs and palbociclib, resulting in sustained inhibition of tumors receiving both treatments
View article: Supplemental figure 2 from Efficacy of SERD/SERM Hybrid-CDK4/6 Inhibitor Combinations in Models of Endocrine Therapy–Resistant Breast Cancer
Supplemental figure 2 from Efficacy of SERD/SERM Hybrid-CDK4/6 Inhibitor Combinations in Models of Endocrine Therapy–Resistant Breast Cancer Open
Supplemental figure 2: SERDs inhibit the constitutive activity of the clinically relevant Y537N,D538G ESR1 double mutant
View article: Supplemental figure 3 from Efficacy of SERD/SERM Hybrid-CDK4/6 Inhibitor Combinations in Models of Endocrine Therapy–Resistant Breast Cancer
Supplemental figure 3 from Efficacy of SERD/SERM Hybrid-CDK4/6 Inhibitor Combinations in Models of Endocrine Therapy–Resistant Breast Cancer Open
Supplemental figure 3: SERDs and palbociclib inhibit breast cancer cell proliferation by independent mechanisms
View article: Data from Efficacy of SERD/SERM Hybrid-CDK4/6 Inhibitor Combinations in Models of Endocrine Therapy–Resistant Breast Cancer
Data from Efficacy of SERD/SERM Hybrid-CDK4/6 Inhibitor Combinations in Models of Endocrine Therapy–Resistant Breast Cancer Open
Purpose: Endocrine therapy, using tamoxifen or an aromatase inhibitor, remains first-line therapy for the management of estrogen receptor (ESR1)–positive breast cancer. However, ESR1 mutations or other ligand-independent ESR1 activation me…
View article: Supplemental figure 5 from Efficacy of SERD/SERM Hybrid-CDK4/6 Inhibitor Combinations in Models of Endocrine Therapy–Resistant Breast Cancer
Supplemental figure 5 from Efficacy of SERD/SERM Hybrid-CDK4/6 Inhibitor Combinations in Models of Endocrine Therapy–Resistant Breast Cancer Open
Supplemental figure 5: IHC analysis of treated PDX tumors indicated on-target activity of bazedoxifene and palbociclib
View article: Supplemental figure 3 from Efficacy of SERD/SERM Hybrid-CDK4/6 Inhibitor Combinations in Models of Endocrine Therapy–Resistant Breast Cancer
Supplemental figure 3 from Efficacy of SERD/SERM Hybrid-CDK4/6 Inhibitor Combinations in Models of Endocrine Therapy–Resistant Breast Cancer Open
Supplemental figure 3: SERDs and palbociclib inhibit breast cancer cell proliferation by independent mechanisms
View article: Supplemental figure 1 from Efficacy of SERD/SERM Hybrid-CDK4/6 Inhibitor Combinations in Models of Endocrine Therapy–Resistant Breast Cancer
Supplemental figure 1 from Efficacy of SERD/SERM Hybrid-CDK4/6 Inhibitor Combinations in Models of Endocrine Therapy–Resistant Breast Cancer Open
Supplemental figure 1: SERDs and SERMs differ in their ability to inhibit ER-dependent stimulation of breast cancer cell proliferation by growth factors
View article: Supplemental figure 1 from Efficacy of SERD/SERM Hybrid-CDK4/6 Inhibitor Combinations in Models of Endocrine Therapy–Resistant Breast Cancer
Supplemental figure 1 from Efficacy of SERD/SERM Hybrid-CDK4/6 Inhibitor Combinations in Models of Endocrine Therapy–Resistant Breast Cancer Open
Supplemental figure 1: SERDs and SERMs differ in their ability to inhibit ER-dependent stimulation of breast cancer cell proliferation by growth factors
View article: Supplemental figure 5 from Efficacy of SERD/SERM Hybrid-CDK4/6 Inhibitor Combinations in Models of Endocrine Therapy–Resistant Breast Cancer
Supplemental figure 5 from Efficacy of SERD/SERM Hybrid-CDK4/6 Inhibitor Combinations in Models of Endocrine Therapy–Resistant Breast Cancer Open
Supplemental figure 5: IHC analysis of treated PDX tumors indicated on-target activity of bazedoxifene and palbociclib
View article: Supplemental figure 4 from Efficacy of SERD/SERM Hybrid-CDK4/6 Inhibitor Combinations in Models of Endocrine Therapy–Resistant Breast Cancer
Supplemental figure 4 from Efficacy of SERD/SERM Hybrid-CDK4/6 Inhibitor Combinations in Models of Endocrine Therapy–Resistant Breast Cancer Open
Supplemental figure 4: Evaluation of pharmacodynamics endpoints confirms on target activity of SERDs and palbociclib, resulting in sustained inhibition of tumors receiving both treatments
View article: Data from Efficacy of SERD/SERM Hybrid-CDK4/6 Inhibitor Combinations in Models of Endocrine Therapy–Resistant Breast Cancer
Data from Efficacy of SERD/SERM Hybrid-CDK4/6 Inhibitor Combinations in Models of Endocrine Therapy–Resistant Breast Cancer Open
Purpose: Endocrine therapy, using tamoxifen or an aromatase inhibitor, remains first-line therapy for the management of estrogen receptor (ESR1)–positive breast cancer. However, ESR1 mutations or other ligand-independent ESR1 activation me…